Raymond James & Associates’s Neurotrope, Inc. Common NTRP Stock Holding History

Raymond James & Associates’s Portfolio NTRP Stock Details NTRP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-11,773	Closed	-$13K	–	3947
2020 Q3	$13K	Hold	11,773	–	–	﹤0.01%	3534
2020 Q2	$14K	Hold	11,773	–	–	﹤0.01%	3467
2020 Q1	$10K	Hold	11,773	–	–	﹤0.01%	3441
2019 Q4	$12K	Hold	11,773	–	–	﹤0.01%	3631
2019 Q3	$10K	Hold	11,773	–	–	﹤0.01%	3567
2019 Q2	$94K	Hold	11,773	–	–	﹤0.01%	3417
2019 Q1	$64K	Sell	11,773 -50	-0.4%	-$215	﹤0.01%	3455
2018 Q4	$42K	Buy	+11,823	New	+$71.6K	﹤0.01%	3400

Other funds holding NTRP

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Raymond James & Associates's NTRP Position: Q4 2020 in Review

Raymond James & Associates sold out of Neurotrope, Inc. Common (NTRP) in Q4 2020, closing a stake of 11,773 shares — an estimated $13K sold.

Raymond James & Associates first reported a position in NTRP in Q4 2018 and held it in 8 quarters. The position peaked at $94K in Q2 2019. 1 fund tracked by Wall St. Rank holds NTRP as of Q4 2020.

Raymond James & Associates reported no remaining Neurotrope, Inc. Common position as of Q4 2020 after selling out during the quarter.
Raymond James & Associates sold 11,773 Neurotrope, Inc. Common shares in Q4 2020, an estimated $13K.
Raymond James & Associates first reported a position in Neurotrope, Inc. Common in Q4 2018 and held it in 8 quarters.
Raymond James & Associates's Neurotrope, Inc. Common position peaked at $94K in Q2 2019.
1 fund tracked by Wall St. Rank held Neurotrope, Inc. Common as of Q4 2020.

Based on Raymond James & Associates's 13F filing for Q4 2020, filed 12 Feb 2021.